Patterson Companies, Inc. ( PDCO Quick Quote PDCO - Free Report) reported adjusted earnings per share (EPS) of 63 cents in second-quarter fiscal 2021, which beat the Zacks Consensus Estimate by 65.8%. Moreover, the bottom line improved 61.5% from the prior-year quarter. The upside came on the back of sustained expense discipline, enhanced mix and solid sales execution. Revenue Details
Net sales in the quarter were $1.55 billion, outpacing the Zacks Consensus Estimate by 8.8%. Also, the top line increased 9.5% year over year.
The company currently distributes products through subsidiaries — Patterson Dental and Patterson Animal Health.
Dental Segment This segment provides a complete range of consumable dental products, equipment, software, turnkey digital solutions and value-added services to dentists, and laboratories throughout North America. In the fiscal second quarter, dental sales grew 11.9% year over year to $631.7 million. Dental Consumable Sales in the sub-segment totaled $357.8 million, up 17.5% year over year. Dental Equipment & Software Sales in the segment climbed 5.3% on a year-over-year basis to $198.1 million. Other This segment comprises technical service, parts and labor, software support services and office supplies. Sales at the segment increased 5.5% on a year-over-year basis to $75.8 million. Animal Health Segment This segment is a leading distributor of veterinary supplies to clinics, public and private institutions and shelters across the United States. In the fiscal second quarter, the segment sales rose 7.8% on a year-over-year basis to $914.2 million. Corporate Sales at the segment were $7.2 million, which improved 21.7% from $5.9 million in the year-ago quarter. Margin Analysis
Gross profit in the reported quarter was $320.4 million, up 6.3% year over year. As a percentage of revenues, gross margin of 20.6% contracted 70 basis points (bps) on a year-over-year basis.
Operating expenses in the reported quarter totaled $246.7 million, declining 22.8% from the prior-year quarter. The company reported operating income of $73.7 million, against the year-ago quarter’s operating loss of $18.1 million. Financial Position
The company exited the fiscal second quarter with cash and cash equivalents of $139.5 million, up from $119.6 million on a sequential basis.
Cumulative net cash used in operating activities in the fiscal second quarter were $423 million, significantly wider than the year-ago quarter’s net cash utilized in operating activities of $14.7 million. Fiscal 2021 Guidance
Patterson Companies refrained from issuing fiscal 2021 financial guidance at this time citing the persistent uncertainty with respect to the COVID-19 pandemic and its impact on business operations.
Patterson Companies ended second-quarter fiscal 2021 on a strong note, wherein both earnings and revenues beat the consensus mark. Moreover, the company witnessed improved performance across its segments in the quarter under review. Prudent cost savings approach and solid sales execution worked well for the stock.
Also, a broad spectrum of products cushions the company against economic downturns in the MedTech space. We believe that a diverse product portfolio, strong veterinary business prospects, accretive acquisitions and strategic partnerships are key catalysts. However, contraction in gross margin remains a headwind. Zacks Rank
Patterson Companies carries a Zacks Rank #3 (Hold).
Earnings of Other MedTech Majors at a Glance
Some better-ranked stocks in the broader medical space that have already announced their quarterly results are
Thermo Fisher Scientific Inc. ( TMO Quick Quote TMO - Free Report) , Align Technology, Inc. ( ALGN Quick Quote ALGN - Free Report) and Bio-Rad Laboratories, Inc. ( BIO Quick Quote BIO - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Align Technology reported third-quarter 2020 adjusted EPS of $2.25, which surpassed the Zacks Consensus Estimate by 281.4%. Revenues of $734.1 million outpaced the consensus mark by 38%. Thermo Fisher reported third-quarter 2020 adjusted EPS of $5.63, beating the Zacks Consensus Estimate by 28.8%. Revenues of $8.52 billion surpassed the consensus mark by 10%. Bio-Rad Laboratories reported third-quarter 2020 adjusted earnings per share (EPS) of $3, which beat the Zacks Consensus Estimate by 62.2%. Revenues of $647.3 million surpassed the consensus mark by 14.5%. Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >>